Respiratory Syncytial Virus

Enhanced Disease Associated with Strong T-Cell Activation

Published in TB and Outbreaks Week, February 1st, 2000

Analysis of T- and B-cell responses to candidate vaccines in outbred human populations may be used to guide the development of protective, non-pathogenic vaccines, according to researchers in England.

In human infants, vaccination against respiratory syncytial virus (RSV) can enhance disease during subsequent natural infection, noted Caroline Maher and colleagues.

Maher et al. reported their study of the correlates of protective immunity at the Joint Congress of the British Society for Immunology and the British Society for Allergy & Clinical Immunology, held November 30-December 3, 1999, in Harrogate, England, UK. Their study was titled "Host...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry